Replies to post #142385 on Biotech Values

[genisi]

Nexavar in lung cancer and KRAS

I’m not sure. One possible reason is that the relevance of KRAS in NSCLC was less established when this study was designed, which was in 2008.

I believe the reason is they have tested treatment correlation with KRAS mutational status in a small phase II in NSCLC and found there was no stat-sig correlation.